Surgery and postoperative radiotherapy a valid treatment for advanced oropharyngeal carcinoma.
Since 1992 we have prospectively included all head and neck cancer patients in our health region in a departmental based register. Our hospital takes care of all head and neck cancer patients in our health region consisting of approximately 1 million people. In 1997, we evaluated the results of the treatment of oropharyngeal cancer in the 1992-1997 period. On the basis of this evaluation, we changed our treatment policy for tonsillar and base of tongue carcinoma. We first changed the treatment for the lesions with worst prognosis, i.e., those with T3-T4 carcinomas, from radiotherapy only, to radical surgery and postoperative radiotherapy. We have since that time increasingly also operated the smaller oropharyngeal carcinomas. The 2 years' overall survival and disease-specific survival for all patients diagnosed in the 1992-1997 period was 56 and 63%, respectively. The results from a similar group of patients in the 6 years' period from 2000 to 2005, after the change in treatment, have increased to 83 and 88%. When we looked at the subgroup of patients in the 2000-2005 period treated with surgery and postoperative radiotherapy, 45 out of 69 patients (65%) presenting with an oropharyngeal cancer were fit for operation. With radical surgery and postoperative radiation therapy, the 2 years overall survival is now 91%. The 2-year disease-specific survival is 96% and the locoregional control is 98%. This is a marked improvement as compared to radiotherapy alone and definitely competitive with modern radiochemotherapy.
Lybak
Stein
S
Department of Otolaryngology/Head & Neck Surgery, Haukeland University Hospital, 5021 Bergen, Norway. stein.lybak@helse-bergen.no
Liavaag
Per Gunnar
PG
Monge
Odd R
OR
Olofsson
Jan
J
D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009664:Norway / Q000453:epidemiology; D009959:Oropharyngeal Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D013517:Otorhinolaryngologic Surgical Procedures / Q000379:methods*; D011184:Postoperative Period; D011379:Prognosis; D011446:Prospective Studies; D018714:Radiotherapy, Adjuvant; D015996:Survival Rate
Ann Otol Rhinol Laryngol. 2007 Feb;116(2):92-9
17388231
Curr Opin Otolaryngol Head Neck Surg. 2005 Aug;13(4):226-32
16012247
Arch Otolaryngol Head Neck Surg. 2008 Nov;134(11):1196-204
19015451
Int J Cancer. 2006 Dec 1;119(11):2620-3
16991119
Oral Oncol. 2003 Jan;39(1):31-6
12457719
J Clin Oncol. 2002 Oct 1;20(19):3964-71
12351593
Curr Opin Otolaryngol Head Neck Surg. 2009 Apr;17(2):88-94
19373958
J Clin Oncol. 2000 Jun;18(11):2219-25
10829041
Laryngoscope. 2009 Mar;119(3):534-40
19235752
Head Neck. 2003 Feb;25(2):123-31
12509795
J Craniomaxillofac Surg. 2000 Feb;28(1):49-55
10851674
Eur Arch Otorhinolaryngol. 2006 Feb;263(2):139-43
16003551
Acta Oncol. 2000;39(8):985-94
11207007
Laryngoscope. 2009 Sep;119(9):1709-19
19572271
Oral Oncol. 2009 Nov;45(11):953-7
19665919
Head Neck. 2006 Jul;28(7):587-94
16475199
Clin Otolaryngol Allied Sci. 1996 Dec;21(6):550-6
9118581
Head Neck. 2009 Feb;31(2):167-74
18853443
Cancer. 2002 Jun 1;94(11):2967-80
12115386
J Clin Oncol. 2004 Jan 1;22(1):69-76
14657228
Eur Arch Otorhinolaryngol. 2009 Dec;266(12):1845-55
19866522
Head Neck. 1998 Dec;20(8):668-73
9790286
Head Neck. 2009 Nov;31(11):1447-55
19431199
Head Neck. 2004 Aug;26(8):660-74
15287033
Laryngoscope. 1994 Dec;104(12):1466-70
7990635
Cancer. 2008 Aug 1;113(3):497-507
18521908